NTRK1 and cancer: David S Hong et al. showed that among 159 patients with TRK fusion-positive cancer who received larotrectinib, 121 out of 153 evaluable patients showed an objective response (79%, 95% CI 72–85), and 24 (16%) showed a complete response (16%) [32].